Monoclonal antibodies against her2 epitope and methods of use thereof

Abstract

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

What is claimed is: 
     
         1 . A method of identifying an antibody or antigen binding fragment thereof that binds a human HER2 receptor at a defined epitope comprising:
 a) contacting an immobilized Her-2 receptor polypeptide with:
 i) a first antibody or antigen binding fragment thereof comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 25); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 26); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 27) and a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 28); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 21); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29) to a solid substrate; and 
 ii) a second antibody or antigen binding fragment thereof 
   (b) determining whether the second antibody competes for binding to HER2 receptor with the first antibody;   wherein when the second antibody competes for binding to HER2 receptor with the first antibody indicates that the second antibody binds the human HER2 receptor at a defined epitope.   
     
     
         2 . The method of  claim 1 , wherein either the first or second antibody or antigen binding fragment thereof is labeled. 
     
     
         3 . The method of  claim 2 , wherein the label is a detectable fluorescent or radioactive marker. 
     
     
         4 . The method of  claim 1 , wherein the immobilized HER2 receptor polypeptide is expressed on a cell surface or on a solid support. 
     
     
         5 . The method of  claim 4 , wherein the cell is a JIMT-1 cell. 
     
     
         6 . The method of  claim 4 , wherein the solid support is a biosensor. 
     
     
         7 . The method of  claim 1 , wherein the first antibody or antigen binding fragment thereof comprises:
 a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence at least 80% identical thereto, and a variable light chain comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence at least 80% identical thereto;   a heavy chain comprising the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence at least 80% identical thereto, and a light chain comprising the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence at least 80% identical thereto;   wherein the antibody or antigen binding fragment bind the HER2 receptor.   
     
     
         8 . The method of  claim 1 , wherein the second antibody or antigen binding fragment is obtained by screening a library comprising antibody or antigen binding domain sequences expressed in display type technologies including phage display, retroviral display, or ribosomal display. 
     
     
         9 . The method of  claim 8 , wherein the bacteriophage displayed library comprises phage carrying randomized pairs of light and heavy chains. 
     
     
         10 . The method of  claim 8 , wherein the second antibody or antigen binding fragment thereof that competes for specific binding to a human HER2 receptor is identified by an in vitro assay comprising enzyme linked immunosorbent assay (ELISA), western blot, immunoprecipitation, or immunofluorescence. 
     
     
         11 . The isolated antibody or antigen binding fragment thereof of  claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody, a domain antibody, a single chain antibody, a Fab fragment, a F(ab′) 2  fragment, a single chain variable fragment (scFv), a scFv-Fc fragment, a single chain antibody (scAb), a domain antibody (dAb), a single domain heavy chain antibody, or a single domain light chain antibody. 
     
     
         12 . The method of  claim 1 , wherein the isolated antibody or antigen binding fragment thereof is a rabbit, mouse, chimeric, humanized or fully human monoclonal antibody. 
     
     
         13 . The method of  claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an IgG isotype. 
     
     
         14 . The method of  claim 1 , wherein the isolated antibody or antigen binding fragment thereof is an IgG1 isotype.